Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 24, Issue 5, 2014, Pages 245-252

  Findling, Robert L ^a   Mcburnett, Keith ^b   White, Carla ^c   Youcha, Sharon ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Shire Pharmaceuticals   (United Kingdom)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANFACINE; PLACEBO; PSYCHOSTIMULANT AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CENTRAL STIMULANT AGENT; DELAYED RELEASE FORMULATION;

ADJUVANT THERAPY; ADOLESCENT HEALTH; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; ETHNICITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPPOSITIONAL DEFIANT DISORDER; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SOMNOLENCE; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; SEVERITY OF ILLNESS INDEX;

ADOLESCENT; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GUANFACINE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX;

EID: 84903195529     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2013.0103     Document Type: Article

References (31)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994
2. Bangs ME, Hazell P, Danckaerts M, Hoare P, Coghill DR, Wehmeier PM, Williams DW, Moore RJ, Levine L: Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics 121:e314-e320, 2008
3. Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, Scherer N: A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 121:e73-e84, 2008
4. Biederman J, Spencer TJ, Newcorn JH, Gao H, Milton DR, Feldman PD, Witte MM: Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: A meta-Analysis of controlled clinical trial data. Psychopharmacology (Berl) 190:31-41, 2007
5. Cantwell DP: Attention deficit disorder: A review of the past 10 years. J Am Acad Child Adolesc Psychiatry 35:978-987, 1996
6. Centers for Disease Control and Prevention: Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children-United States, 2003 and 2007. MMWR Morb Mortal Wkly Rep 59:1439-1443, 2010
7. Conners CK: Conners Rating Scales-Revised. Toronto, ON: Multi-Health Systems, Inc.; 1997
8. Connor DF, Doerfler LA: ADHD with comorbid oppositional defiant disorder or conduct disorder: Discrete or nondistinct disruptive behavior disorders? J Atten Disord 12:126-134, 2008
9. Connor DF, Findling RL, Kollins SH, Sallee F, Lopez FA, Lyne A, Tremblay G: Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: A randomized, double-blind, placebo-controlled trial. CNS Drugs 24:755-768, 2010
10. Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A: Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebocontrolled Italian study. Eur Neuropsychopharmacol 19:822-834, 2009
11. Dittmann RW, Schacht A, Helsberg K, Schneider-Fresenius C, Lehmann M, Lehmkuhl G, Wehmeier PM: Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A doubleblind, randomized, multicenter trial in Germany. J Child Adolesc Psychopharmacol 21:97-110, 2011
12. Harpold T, Biederman J, Gignac M, Hammerness P, Surman C, Potter A, Mick E: Is oppositional defiant disorder a meaningful diagnosis in adults? Results from a large sample of adults with ADHD. J Nerv Ment Dis 195:601-605, 2007
13. Hazell P, Becker K, Nikkanen EA, Trzepacz PT, Tanaka Y, Tabas L, D'Souza DN, Witcher J, Long A, Ponsler G, Dittmann RW: Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Atten Defic Hyperact Disord 1:201-210, 2009
14. INTUNIV: INTUNIV- (guanfacine) extended-release tablets [package insert]. Wayne, PA: Shire Pharmaceuticals LLC; 2011
15. Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF: Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord 8:45-52, 2004
16. Kollins SH, Jain R, Brams M, Segal S, Findling RL, Wigal SB, Khayrallah M: Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics 127:e1406-e1413, 2011
17. Lopez FA, Ginsberg LD, Arnold V: Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/ hyperactivity disorder: A secondary analysis. Postgrad Med 120:89-102, 2008
18. Marchant BK, Reimherr FW, Robison RJ, Olsen JL, Kondo DG: Methylphenidate transdermal system in adult ADHD and impact on emotional and oppositional symptoms. J Atten Disord 15:295-304, 2011
19. Martel MM, Gremillion M, Roberts B, von EA, Nigg JT: The structure of childhood disruptive behaviors. Psychol Assess 22:816-826, 2010
20. Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, McCracken JT, Swanson JM, Lopez M: The Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:642-657, 2006
21. Sallee FR, Lyne A, Wigal T, McGough JJ: Long-Term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 19:215-226, 2009a.
22. Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J: Guanfacine extended release in children and adolescents with attention-deficit/ hyperactivity disorder: A placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 48:155-165, 2009b.
23. Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E, Arnsten AF, Cohen DJ, Leckman JF: A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 158:1067-1074, 2001
24. Spencer TJ, Abikoff HB, Connor DF, Biederman J, Pliszka SR, Boellner S, Read SC, Pratt R: Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of oppositional defiant disorder with or without comorbid attentiondeficit/ hyperactivity disorder in school-Aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study. Clin Ther 28: 402-418, 2006
25. Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR: Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attentiondeficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 19:501-510, 2009
26. Steiner H, Remsing L: Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 46:126-141, 2007
27. van Wyk GW, Hazell PL, Kohn MR, Granger RE, Walton RJ: How oppositionality, inattention, and hyperactivity affect response to atomoxetine versus methylphenidate: A pooled meta-Analysis. J Atten Disord 16:314-324, 2012
28. Waxmonsky JG, Waschbusch DA, Akinnusi O, Pelham WE: A comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 21:21-32, 2011
29. Waxmonsky JG, Waschbusch DA, Pelham WE, Draganac-Cardona L, Rotella B, Ryan L: Effects of atomoxetine with and without behavior therapy on the school and home functioning of children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 71:1535-1551, 2010
30. Wilens TE, Bukstein O, Brams M, Cutler AJ, Childress A, Rugino T, Lyne A, Grannis K, Youcha S: A controlled trial of extendedrelease guanfacine and psychostimulants for attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 51: 74-85, 2012
31. Wilens TE, Spencer TJ: The stimulants revisited. Child Adolesc Psychiatr Clin N Am 9:573-603, viii, 2000